A crossover randomized clinical trial (N = 33 patients with AD who received CSHI or thrice-daily conventional therapy for a 3-month period), found that a 10mg/m2 daily dose of CSHI normalized cortisol and ACTH levels in the morning, and patients 24-hour cortisol curves approached normal circadian variation compared with conventional oral replacement. Here, POMC is linked to Alzheimer disease.